182 related articles for article (PubMed ID: 27746500)
1. Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital.
Petnikota H; Madhuri V; Gangadharan S; Agarwal I; Antonisamy B
Indian J Orthop; 2016 Sep; 50(5):551-557. PubMed ID: 27746500
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
[TBL] [Abstract][Full Text] [Related]
4. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD; Skalsky A; McDonald CM
J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
[TBL] [Abstract][Full Text] [Related]
5. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.
Shieh PB; Elfring G; Trifillis P; Santos C; Peltz SW; Parsons JA; Apkon S; Darras BT; Campbell C; McDonald CM; ; ; ;
J Comp Eff Res; 2021 Dec; 10(18):1337-1347. PubMed ID: 34693725
[No Abstract] [Full Text] [Related]
6. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
[TBL] [Abstract][Full Text] [Related]
7. Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: A randomized, open-label trial.
Kochar GS; Sondhi V; Kabra SK; Yadav SL; Dwivedi SN; Gulati S
Muscle Nerve; 2022 Jan; 65(1):60-66. PubMed ID: 34617309
[TBL] [Abstract][Full Text] [Related]
8. [Prednisolone treatment for Duchenne muscular dystrophy].
Shimomura H; Fujii T; Miyajima T; Kumada T; Kimura N; Oda N; Saito K
No To Hattatsu; 2011 Jan; 43(1):24-9. PubMed ID: 21400928
[TBL] [Abstract][Full Text] [Related]
9. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
Alman BA; Raza SN; Biggar WD
J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.
Liu G; Lipari P; Mollin A; Jung S; Teplova I; Li W; Ying L; More V; Lennox W; Yeh S; McGann E; Moon YC; Rice C; Huarte E; Gruszka B; Ray B; Goodwin E; Buckendahl P; Yurkow E; Braughton B; Narasimhan J; Welch E; Voronin G; Weetall M
Hum Mol Genet; 2024 Jan; 33(3):211-223. PubMed ID: 37819629
[TBL] [Abstract][Full Text] [Related]
11. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
[TBL] [Abstract][Full Text] [Related]
12. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
[No Abstract] [Full Text] [Related]
13. Steroids in Duchenne muscular dystrophy--deflazacort trial.
Mesa LE; Dubrovsky AL; Corderi J; Marco P; Flores D
Neuromuscul Disord; 1991; 1(4):261-6. PubMed ID: 1822804
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Balaban B; Matthews DJ; Clayton GH; Carry T
Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
[TBL] [Abstract][Full Text] [Related]
15. Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial.
Reddy C; Patil AN; Suthar R; Sankhyan N; Sirari T; Kumar A; Bhattacharjee S; Saxena S; Saini AG; Sahu JK
Eur J Paediatr Neurol; 2022 May; 38():77-84. PubMed ID: 35500465
[TBL] [Abstract][Full Text] [Related]
16. Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1.
McDonald CM; Mayer OH; Hor KN; Miller D; Goemans N; Henricson EK; Marden JR; Freimark J; Lane H; Zhang A; Frean M; Trifillis P; Koladicz K; Signorovitch J;
J Neuromuscul Dis; 2023; 10(1):67-79. PubMed ID: 36565131
[TBL] [Abstract][Full Text] [Related]
17. Cardiorespiratory Progression Over 5 Years and Role of Corticosteroids in Duchenne Muscular Dystrophy: A Single-Site Retrospective Longitudinal Study.
Trucco F; Domingos JP; Tay CG; Ridout D; Maresh K; Munot P; Sarkozy A; Robb S; Quinlivan R; Riley M; Burch M; Fenton M; Wallis C; Chan E; Abel F; Manzur AY; Muntoni F
Chest; 2020 Oct; 158(4):1606-1616. PubMed ID: 32387519
[TBL] [Abstract][Full Text] [Related]
18. The role of corticosteroids in muscular dystrophy: a critical appraisal.
Angelini C
Muscle Nerve; 2007 Oct; 36(4):424-35. PubMed ID: 17541998
[TBL] [Abstract][Full Text] [Related]
19. Deflazacort.
Joshi N; Rajeshwari K
J Postgrad Med; 2009; 55(4):296-300. PubMed ID: 20083885
[TBL] [Abstract][Full Text] [Related]
20. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study.
Wong BL; Cook T; Miller H
J Comp Eff Res; 2022 Aug; 11(11):779-786. PubMed ID: 35713895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
